Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the exercise of the over-allotment option granted to the underwriters to purchase 921,500 additional shares of common stock, at a public offering price of $4.00 per share, in connection with its previously announced initial public offering of 10,750,000 shares of common stock, bringing the total gross proceeds from the offering to $46,686,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Regado Biosciences. All of the common stock was offered by Regado Biosciences. The company's common stock is listed on The NASDAQ Capital Market under the trading symbol "RGDO."
Cowen and Company, LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering. Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 21, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: [email protected].
Exercise enhances memory for up to 24 hours, study finds